MedTrace Logo

Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy

NCT01521611 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2019-04-08

No results posted yet for this study

Summary

To determine whether a radiolabelled antibody that targets the bone marrow (the 'anti-CD66') can be administered safely to patients as part of the preparative treatment prior to haematopoietic stem cell transplantation ('a bone marrow transplant'). Can the radiolabelled antibody be shown to effectively target the bone marrow in these patients. If it can, could this result in better outcomes after transplantation.

Conditions

Interventions

RADIATION

Targeted radiotherapy

Yttrium-90 labelled anti-CD66 monoclonal antibody.

Sponsors & Collaborators

  • Royal Free and University College Medical School

    collaborator OTHER

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Kim H Orchard, MBBS PhD · University Hospital Southampton NHS Foundation Trust

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2017-07-01
Completion
2018-07-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01521611 on ClinicalTrials.gov